Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFκB activity within two separate high-throughput screens of NFκB activation

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 1, 2008, Pages 329-335

  Xie, Yuli ^a   Deng, ShiXian ^a   Thomas, Craig J ^b   Liu, Yidong ^a   Zhang, Ya Qin ^b   Rinderspacher, Alison ^a   Huang, Wenwei ^b   Gong, Gangli ^a   Wyler, Michael ^c   Cayanis, Efithia ^c   Aulner, Nathalie ^c   Többen, Udo ^c   Chung, Caty ^d   Pampou, Sergey ^c   Southall, Noel ^b   Vidović, Dušica ^d   Schürer, Stephan ^d   Branden, Lars ^c   Davis, R Eric ^e   Staudt, Louis M ^e   Inglese, James ^b   Austin, Christopher P ^b   Landry, Donald W ^a   Smith, Deborah H ^c   Auld, Douglas S ^b   more..

^a Division of Clinical Pharmacology   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^c Columbia Genome Center ^*  (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

NF B inhibitor

Indexed keywords

BENZENESULFONAMIDE DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (QUINOLIN 8 YL)BENZENESULFONAMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CULTURE MEDIUM; DOWN REGULATION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; STRUCTURE ANALYSIS; UMBILICAL VEIN;

COMBINATORIAL CHEMISTRY TECHNIQUES; DOWN-REGULATION; NF-KAPPA B; QUINOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 37649007911     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.100     Document Type: Article

References (26)

1. Gilmore T.D. Oncogene 25 (2006) 6680
2. Perkins N.D. Nat. Rev. Mol. Cell Biol. 8 (2007) 49
3. Sen R., and Baltimore D. Cell 47 (1986) 921
4. Aggarwal B.B. Expert Opin. Ther. Targets 11 (2007) 109
5. Hoffmann A., Natoli G., and Ghosh G. Oncogene 25 (2006) 6706
6. D'Acquisto F.D., and Ianaro A. Curr. Opin. Pharmacol. 6 (2006) 387
7. Gilmore T.D., and Herscovitch M. Oncogene 25 (2006) 6887
8. Austin C.P., Brady L.S., Insel T.R., and Collins F.S. Science 306 (2004) 1138
9. Davis R.E., Zhang Y.-Q., Southall N., Staudt L.M., Austin C.P., Inglese J., and Auld D.S. Assay Drug Dev. Technol. 5 (2007) 85
10. Davis R.E., Brown K.D., Siebenlist U., and Staudt L.M. J. Exp. Med. 184 (2001) 1861
11. Okamoto T., Sanda T., and Asamitsu K. Curr. Pharm. Des. 13 (2007) 447
12. Lam L.T., Davis R.E., Pierce J., Hepperle M., Xu Y., Hottelet M., Nong Y., Wen D., Adams J., Dang L., and Staudt L.M. Clin. Cancer Res. 11 (2005) 28
13. Ngo V.N., Davis R.E., Lamy L., Yu X., Zhao H., Lenz G., Lam L.T., Dave S., Yang L., Powell J., and Staudt L.M. Nature 441 (2006) 106
14. Mayer T., Jagla B., Wyler M., Kelly P., Aulner N., Beard M., Barger G., Toebben U., Smith D.H., Branden L., and Rothman J. Methods Enzyme 414 (2006) 266
15. 14 HUVEC grown for fewer than 8 passages were seeded at 3000 cells/well in 384-well view plates. For the concentration-response curves, one of two alternate protocols was used: compounds were added to a final concentration of 10 μM in media, 0.33% DMSO, and serially diluted by 1:3, or compounds were added to a final concentration of 8 μM and serially diluted by 1:2. In either case, this produced eight data points. After a 3.5-h incubation with compound, cells were stimulated using 10 μM TNFα for 30 min. Fixed and permeabilized cells were stained with Hoechst to visualize the nuclei, and with mouse anti-p65 (Invitrogen) followed by a secondary antibody conjugated to Alexa Fluor 647 (Invitrogen). Images were scanned using the In Cell Analyzer 3000 (GE Healthcare) and analyzed using the Nuclear Trafficking module.
16. Lee D.H., and Goldberg A.L. J. Biol. Chem. 271 (1996) 27280
17. Kamthong P.J., and Wu M.-C. Biochem. J. 356 (2001) 525
18. Izban K.F., Ergin M., Qin J.-Z., Martinez R.L., Pooley R.J., Saeed S., and Alkan S. Hum. Pathol. 31 (2000) 1482
19. Pierce J.W., Schoenleber R., Jesmok G., Best J., Moore S.A., Collins T., and Gerritsen M.E. J. Biol. Chem. 272 (1997) 21096
20. Palanki M.S.S., Erdman P.E., Ren M., Suto M., Bennett B.L., Manning A., Ransone L., Spooner C., Desai S., Ow A., Totsuka R., Tsao P., and Toriumi W. Bioorg. Med. Chem. Lett. 13 (2003) 4077
21. ++H): 344.1. For general procedure for analogues of 5, see Ref. 22.
22. Xie, Y.; Gong, G.; Liu, Y.; Deng, S.; Rinderspacher, K. A.; Branden, L.; Landry, D. W. Tetrahedron Lett., submitted for publication.
23. Shoichet B.K. J. Med. Chem. 49 (2006) 7274
24. Feng B.Y., Simeonov A., Jadhav A., Babaoglu K., Inglese J., Shoichet B.K., and Austin C.P. J. Med. Chem. 50 (2007) 2385
25. Inglese J., Johnson R.L., Simeonov A., Xia M., Zheng W., Austin C.P., and Auld D.S. Nat. Chem. Biol. 3 (2007) 466
26. Swinney D.C., Xu Y.-Z., Scarafia L., Lee I., Mak A., Gan Q.-F., Ramesha C., Mulkins M., Dunn J., So O.-Y., Biegel T., Dinh M., Volkel P., Barnett J., Dalrymple S., Lee S., and Huber M. J. Biol. Chem. 277 (2002) 23573